Peel Therapeutics shared on LinkedIn:
“We are proud to share that Peel Therapeutics was selected as one of five finalists for the Inaugural Prix Galien Patient First Award in Honor of Michael J. Fox (Private Sector-Led Initiatives), chosen from over 40 nominees ranging from global pharmaceutical companies to emerging biotechs.
PEEL-224, our lead clinical asset, reimagines cancer treatment for patients: engineered for better efficacy with fewer debilitating side effects.
Thank you to The Galien Foundation and the Prix Galien Patient First Award judges for recognizing our commitment to putting patients first!”
To which Joshua Schiffman, CEO and Co-Founder of Peel Therapeutics, added:
“Incredible news!
PEEL-224 was selected last week as top-5 finalist for the Inaugural Prix Galien Patient First Award in Honor of Michael J. Fox.
Feeling very proud of our company and the entire team working so hard to bring better medicines to children and adults with cancer!”
About PEEL-224
Molecules in nature
PEEL-224 is a nanocarrier linked to 4 small molecules developed for the treatment of cancer.
The active molecule of PEEL-224 derives from camptothecin, a naturally occurring compound found in the Chinese Happy Tree thought to have evolved as a plant defense mechanism.
Camptothecin and its derivatives inhibit topoisomerase 1 (TOP1) which results in DNA breaks, effectively killing dividing cells.
By engineering the natural molecule and conjugating it with a synthetic polymer, PEEL-224 is designed to improve efficacy while limiting toxicity.
Impact for patients
The robust preclinical data is extremely promising, showing that PEEL-224 leads to a sustained complete response in the most aggressive solid tumors in some cases for more than six months.
The molecular structure of Peel’s drug prevents its efflux from cancer cells through the ABCG2 multidrug transporter pump, meaning tumors are less likely to become resistant to PEEL-224 treatment and this drug overcomes irinotecan resistance.
The PEEL-224 manufacturing process is optimized, scaled for the clinic and has advanced rapidly to patients.
Source: Peel Therapeutics
Other articles about Peel Therapeutics and PEEL-224 on OncoDaily.